Key near-term catalysts are the Phase 2 MoMeNtum MMN top-line results in December 2026 and CAPTIVATE Part A CIDP results by YE 2027. The 75% interim response rate in CAPTIVATE supports the program's potential, but the stock remains a binary event-driven story with no approved products or revenue.
Price Chart
Executive Summary
Dianthus Therapeutics reported Q3 2026 financial results with a net loss of $46.6M ($0.81 per share), wider than the $36.8M loss in Q3 2025 but narrower on a per-share basis due to a higher share count. The company highlighted a 75% response rate in the CAPTIVATE CIDP trial interim analysis and maintained a $1.2B cash runway into 2030. No revenue or EPS consensus was provided for a verdict, but the net loss per share improved year-over-year from -$0.97 to -$0.81.
Key Financial Metrics
Key Facts
- Net loss for Q3 2026 was $46.6M or $0.81 per share, vs $36.8M or $0.97 per share in Q3 2025
- Cash and investments of approximately $1.2B as of September 30, 2026, providing runway into 2030
- 75% response rate observed in interim responder analysis of Phase 3 CAPTIVATE trial in CIDP
- Phase 2 MoMeNtum trial in MMN top-line results on track for December 2026
- Phase 3 EMERGE trial in gMG initiated in June 2026, top-line results expected in 2H 2028
- DNTH212 Phase 1 SAD Part A healthy volunteer data expected in Q1 2027
- DNTH312 on track to be Phase 1 ready by YE 2027
- R&D expenses were $45.6M for Q3 2026, up from $32.5M in Q3 2025
- G&A expenses were $14.1M for Q3 2026, up from $8.2M in Q3 2025
- License revenue was $1.2M for Q3 2026 vs $0.4M in Q3 2025
Financial Impact
Net loss of $46.6M in Q3 2026, wider than $36.8M in Q3 2025; cash position stable at $1.2B
Risk Factors
- Clinical-stage biotech with no approved products or commercial revenue
- Net loss widening year-over-year as R&D spending increases for multiple trials
- All pipeline candidates are investigational and may fail in later-stage trials
- Long timelines to potential approval: gMG Phase 3 results not expected until 2H 2028
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001690585-26-000039 |
| Document: dnth-20261104.htm | 0001690585-26-000039 |
| Document: 0001690585-26-000039-index-headers.html | 0001690585-26-000039 |
| Document: 0001690585-26-000039-index.html | 0001690585-26-000039 |
| Document: 0001690585-26-000039.txt | 0001690585-26-000039 |
| 8-K Data (Synthetic) | 0001690585-26-000039 |
Track record
23 reports on DNTH
7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 Viewing No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers